Search
Now showing items 1-10 of 27
Microbicides & their implications in HIV prevention.
(MedKnow Publications., 2010)
No abstract available.
Overview of microbicides for the prevention of human immunodeficiency virus.
(Elsevier., 2012)
Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four ...
HIV-prevention science at a crossroads: advances in reducing sexual risk.
(Lippincott Williams & Wilkins., 2009)
Purpose of review—We review the current state of evidence-based prevention strategies for reducing sexual transmission of HIV. The combined programmatic and scientific efforts through 2008 to reduce sexual transmission of ...
An adaptive design to bridge the gap between phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
(Sage., 2012)
Background. Vaginally and rectally applied microbicides are being developed to
help prevent sexual acquisition of HIV. Due to the lack of surrogate outcomes, the
path toward licensure typically moves directly from expanded ...
Design challenges facing clinical trials of the effectiveness of new HIV prevention technologies.
(Lippincott Williams & Wilkins., 2012)
Recent successes of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV infection
have raised questions whether further placebo controlled trials of new HIV-prevention
technologies are ethically justifiable. ...
Topical microbicides - What's new?
(Lippincott Williams & Wilkins., 2013)
Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
PRO 2000: next steps for microbicide development.
(Future Medicine., 2009)
No abstract available.
Antiretroviral prophylaxis: a defining moment in HIV control.
(Elsevier., 2011)
No abstract available.
Adolescents and HIV clinical trials: ethics, culture, and context.
(Elsevier., 2007)
One quarter of HIV infections globally occur among young people 15-24 years of age and more than half of all new infections are to people younger than 25 years. Clearly, there is a need to identify and implement effective ...
Results of effectiveness trials of PRO 2000 gel: lessons for future microbicide trials.
(Future Medicine., 2010)
No abstract available.